a salmonicida atcc 33658t Search Results


aeromonas salmonicida subsp salmonicida a449  (ATCC)
95
ATCC aeromonas salmonicida subsp salmonicida a449
Aeromonas Salmonicida Subsp Salmonicida A449, supplied by ATCC, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/a+salmonicida+atcc+33658t/us11021695-60-38-36?v=ATCC
Average 95 stars, based on 1 article reviews
aeromonas salmonicida subsp salmonicida a449 - by Bioz Stars, 2026-07
95/100 stars
  Buy from Supplier
33656t vpi 0990 gcf 000020605 1 complete  (ATCC)
93
ATCC 33656t vpi 0990 gcf 000020605 1 complete
33656t Vpi 0990 Gcf 000020605 1 Complete, supplied by ATCC, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/a+salmonicida+atcc+33658t/pmc11019791__msystems__01401___23___s0009-3-3-2?v=ATCC
Average 93 stars, based on 1 article reviews
33656t vpi 0990 gcf 000020605 1 complete - by Bioz Stars, 2026-07
93/100 stars
  Buy from Supplier
aeromonas salmonicida subsp salmonicida atcc 33658  (ATCC)
96
ATCC aeromonas salmonicida subsp salmonicida atcc 33658
Aeromonas Salmonicida Subsp Salmonicida Atcc 33658, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/a+salmonicida+atcc+33658t/10__4067_slash_s0718___19572010000300003-85-13-17?v=ATCC
Average 96 stars, based on 1 article reviews
aeromonas salmonicida subsp salmonicida atcc 33658 - by Bioz Stars, 2026-07
96/100 stars
  Buy from Supplier
antibody against nedd9  (Santa Cruz Biotechnology)
92
Santa Cruz Biotechnology antibody against nedd9
Figure 4. Loss of <t>NEDD9</t> or inhibition of BCL-XL renders PIK3CA-mutant gastric cancer cells hypersensitive to BYL719 treatment by increasing cell-cycle arrest and cell death, respectively. A, Western blot of NEDD9 expression in parental and NEDD9-knockout AGS cells. B, GI50 curve of BYL719 in parental and NEDD9-knockout AGS cells measured by CellTiter Glo at 3 days. C, Representative BrdU plots of AGS parental and NEDD9-knockout cells treated with either DMSO or 2 mmol/L BYL719 for 24 hours. D, Reduction in S phase in parental and NEDD9-knockout AGS cells after 24 hours of treatment with 2 mmol/L BYL719. E, Increase in cells in G0–G1 and G2–M phase after 24 hours of treatment with 2 mmol/L BYL719. F, GI50 curve of BYL719 only and the addition of 500 nmol/L A-1331852 measured by CellTiter Glo at 3 days. G, Cells were treated with 1 mmol/L BYL719 or 500 nmol/L A-1331852 alone and in combination. Cell viability was measured by Trypan Blue exclusion after 3 days. H, Cells were treated with 1 mmol/L BYL719 or 500 nmol/L A-1331852 alone and in combination. After 24 hours, cellswere harvested and stained for activated caspase- 3 for flow cytometry. For all, error bars show mean SEM. For experiments in B, F, and H; n ¼ 3. For experiments in D and E, n ¼ 5. For experiments in G; n ¼ 6; , P < 0.05; , P < 0.01; , P < 0.005; , P < 0.001.
Antibody Against Nedd9, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/a+salmonicida+atcc+33658t/10__1158_slash_1541___7786__mcr___23___0034-118-0-9?v=Santa+Cruz+Biotechnology
Average 92 stars, based on 1 article reviews
antibody against nedd9 - by Bioz Stars, 2026-07
92/100 stars
  Buy from Supplier
aeromonas salmonicida ncimb 1102  (NCIMB Ltd)
90
NCIMB Ltd aeromonas salmonicida ncimb 1102
Figure 4. Loss of <t>NEDD9</t> or inhibition of BCL-XL renders PIK3CA-mutant gastric cancer cells hypersensitive to BYL719 treatment by increasing cell-cycle arrest and cell death, respectively. A, Western blot of NEDD9 expression in parental and NEDD9-knockout AGS cells. B, GI50 curve of BYL719 in parental and NEDD9-knockout AGS cells measured by CellTiter Glo at 3 days. C, Representative BrdU plots of AGS parental and NEDD9-knockout cells treated with either DMSO or 2 mmol/L BYL719 for 24 hours. D, Reduction in S phase in parental and NEDD9-knockout AGS cells after 24 hours of treatment with 2 mmol/L BYL719. E, Increase in cells in G0–G1 and G2–M phase after 24 hours of treatment with 2 mmol/L BYL719. F, GI50 curve of BYL719 only and the addition of 500 nmol/L A-1331852 measured by CellTiter Glo at 3 days. G, Cells were treated with 1 mmol/L BYL719 or 500 nmol/L A-1331852 alone and in combination. Cell viability was measured by Trypan Blue exclusion after 3 days. H, Cells were treated with 1 mmol/L BYL719 or 500 nmol/L A-1331852 alone and in combination. After 24 hours, cellswere harvested and stained for activated caspase- 3 for flow cytometry. For all, error bars show mean SEM. For experiments in B, F, and H; n ¼ 3. For experiments in D and E, n ¼ 5. For experiments in G; n ¼ 6; , P < 0.05; , P < 0.01; , P < 0.005; , P < 0.001.
Aeromonas Salmonicida Ncimb 1102, supplied by NCIMB Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/a+salmonicida+atcc+33658t/pm23324417-39-10-14?v=NCIMB+Ltd
Average 90 stars, based on 1 article reviews
aeromonas salmonicida ncimb 1102 - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
spoilage organisms  (ATCC)
93
ATCC spoilage organisms
Figure 4. Loss of <t>NEDD9</t> or inhibition of BCL-XL renders PIK3CA-mutant gastric cancer cells hypersensitive to BYL719 treatment by increasing cell-cycle arrest and cell death, respectively. A, Western blot of NEDD9 expression in parental and NEDD9-knockout AGS cells. B, GI50 curve of BYL719 in parental and NEDD9-knockout AGS cells measured by CellTiter Glo at 3 days. C, Representative BrdU plots of AGS parental and NEDD9-knockout cells treated with either DMSO or 2 mmol/L BYL719 for 24 hours. D, Reduction in S phase in parental and NEDD9-knockout AGS cells after 24 hours of treatment with 2 mmol/L BYL719. E, Increase in cells in G0–G1 and G2–M phase after 24 hours of treatment with 2 mmol/L BYL719. F, GI50 curve of BYL719 only and the addition of 500 nmol/L A-1331852 measured by CellTiter Glo at 3 days. G, Cells were treated with 1 mmol/L BYL719 or 500 nmol/L A-1331852 alone and in combination. Cell viability was measured by Trypan Blue exclusion after 3 days. H, Cells were treated with 1 mmol/L BYL719 or 500 nmol/L A-1331852 alone and in combination. After 24 hours, cellswere harvested and stained for activated caspase- 3 for flow cytometry. For all, error bars show mean SEM. For experiments in B, F, and H; n ¼ 3. For experiments in D and E, n ¼ 5. For experiments in G; n ¼ 6; , P < 0.05; , P < 0.01; , P < 0.005; , P < 0.001.
Spoilage Organisms, supplied by ATCC, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/a+salmonicida+atcc+33658t/pm40005614-51-8-12?v=ATCC
Average 93 stars, based on 1 article reviews
spoilage organisms - by Bioz Stars, 2026-07
93/100 stars
  Buy from Supplier
aeromonas salmonicida subsp salmonicida  (ATCC)
99
ATCC aeromonas salmonicida subsp salmonicida
Figure 4. Loss of <t>NEDD9</t> or inhibition of BCL-XL renders PIK3CA-mutant gastric cancer cells hypersensitive to BYL719 treatment by increasing cell-cycle arrest and cell death, respectively. A, Western blot of NEDD9 expression in parental and NEDD9-knockout AGS cells. B, GI50 curve of BYL719 in parental and NEDD9-knockout AGS cells measured by CellTiter Glo at 3 days. C, Representative BrdU plots of AGS parental and NEDD9-knockout cells treated with either DMSO or 2 mmol/L BYL719 for 24 hours. D, Reduction in S phase in parental and NEDD9-knockout AGS cells after 24 hours of treatment with 2 mmol/L BYL719. E, Increase in cells in G0–G1 and G2–M phase after 24 hours of treatment with 2 mmol/L BYL719. F, GI50 curve of BYL719 only and the addition of 500 nmol/L A-1331852 measured by CellTiter Glo at 3 days. G, Cells were treated with 1 mmol/L BYL719 or 500 nmol/L A-1331852 alone and in combination. Cell viability was measured by Trypan Blue exclusion after 3 days. H, Cells were treated with 1 mmol/L BYL719 or 500 nmol/L A-1331852 alone and in combination. After 24 hours, cellswere harvested and stained for activated caspase- 3 for flow cytometry. For all, error bars show mean SEM. For experiments in B, F, and H; n ¼ 3. For experiments in D and E, n ¼ 5. For experiments in G; n ¼ 6; , P < 0.05; , P < 0.01; , P < 0.005; , P < 0.001.
Aeromonas Salmonicida Subsp Salmonicida, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/a+salmonicida+atcc+33658t/10__1128_slash_jcm__41__9__4318___4323__2003-21-0-4?v=ATCC
Average 99 stars, based on 1 article reviews
aeromonas salmonicida subsp salmonicida - by Bioz Stars, 2026-07
99/100 stars
  Buy from Supplier
vibrio mimicus atcc 33653t  (ATCC)
93
ATCC vibrio mimicus atcc 33653t
Figure 4. Loss of <t>NEDD9</t> or inhibition of BCL-XL renders PIK3CA-mutant gastric cancer cells hypersensitive to BYL719 treatment by increasing cell-cycle arrest and cell death, respectively. A, Western blot of NEDD9 expression in parental and NEDD9-knockout AGS cells. B, GI50 curve of BYL719 in parental and NEDD9-knockout AGS cells measured by CellTiter Glo at 3 days. C, Representative BrdU plots of AGS parental and NEDD9-knockout cells treated with either DMSO or 2 mmol/L BYL719 for 24 hours. D, Reduction in S phase in parental and NEDD9-knockout AGS cells after 24 hours of treatment with 2 mmol/L BYL719. E, Increase in cells in G0–G1 and G2–M phase after 24 hours of treatment with 2 mmol/L BYL719. F, GI50 curve of BYL719 only and the addition of 500 nmol/L A-1331852 measured by CellTiter Glo at 3 days. G, Cells were treated with 1 mmol/L BYL719 or 500 nmol/L A-1331852 alone and in combination. Cell viability was measured by Trypan Blue exclusion after 3 days. H, Cells were treated with 1 mmol/L BYL719 or 500 nmol/L A-1331852 alone and in combination. After 24 hours, cellswere harvested and stained for activated caspase- 3 for flow cytometry. For all, error bars show mean SEM. For experiments in B, F, and H; n ¼ 3. For experiments in D and E, n ¼ 5. For experiments in G; n ¼ 6; , P < 0.05; , P < 0.01; , P < 0.005; , P < 0.001.
Vibrio Mimicus Atcc 33653t, supplied by ATCC, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/a+salmonicida+atcc+33658t/10__1128_slash_aem__00712___11-63-35-37?v=ATCC
Average 93 stars, based on 1 article reviews
vibrio mimicus atcc 33653t - by Bioz Stars, 2026-07
93/100 stars
  Buy from Supplier
e rectale atcc 33656t  (ATCC)
90
ATCC e rectale atcc 33656t
Figure 4. Loss of <t>NEDD9</t> or inhibition of BCL-XL renders PIK3CA-mutant gastric cancer cells hypersensitive to BYL719 treatment by increasing cell-cycle arrest and cell death, respectively. A, Western blot of NEDD9 expression in parental and NEDD9-knockout AGS cells. B, GI50 curve of BYL719 in parental and NEDD9-knockout AGS cells measured by CellTiter Glo at 3 days. C, Representative BrdU plots of AGS parental and NEDD9-knockout cells treated with either DMSO or 2 mmol/L BYL719 for 24 hours. D, Reduction in S phase in parental and NEDD9-knockout AGS cells after 24 hours of treatment with 2 mmol/L BYL719. E, Increase in cells in G0–G1 and G2–M phase after 24 hours of treatment with 2 mmol/L BYL719. F, GI50 curve of BYL719 only and the addition of 500 nmol/L A-1331852 measured by CellTiter Glo at 3 days. G, Cells were treated with 1 mmol/L BYL719 or 500 nmol/L A-1331852 alone and in combination. Cell viability was measured by Trypan Blue exclusion after 3 days. H, Cells were treated with 1 mmol/L BYL719 or 500 nmol/L A-1331852 alone and in combination. After 24 hours, cellswere harvested and stained for activated caspase- 3 for flow cytometry. For all, error bars show mean SEM. For experiments in B, F, and H; n ¼ 3. For experiments in D and E, n ¼ 5. For experiments in G; n ¼ 6; , P < 0.05; , P < 0.01; , P < 0.005; , P < 0.001.
E Rectale Atcc 33656t, supplied by ATCC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/a+salmonicida+atcc+33658t/10__1128_slash_jb__05637___11-46-12-14?v=ATCC
Average 90 stars, based on 1 article reviews
e rectale atcc 33656t - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
a salmonicida hg3 atcc 33658tb united kingdom fish  (ATCC)
94
ATCC a salmonicida hg3 atcc 33658tb united kingdom fish
Figure 4. Loss of <t>NEDD9</t> or inhibition of BCL-XL renders PIK3CA-mutant gastric cancer cells hypersensitive to BYL719 treatment by increasing cell-cycle arrest and cell death, respectively. A, Western blot of NEDD9 expression in parental and NEDD9-knockout AGS cells. B, GI50 curve of BYL719 in parental and NEDD9-knockout AGS cells measured by CellTiter Glo at 3 days. C, Representative BrdU plots of AGS parental and NEDD9-knockout cells treated with either DMSO or 2 mmol/L BYL719 for 24 hours. D, Reduction in S phase in parental and NEDD9-knockout AGS cells after 24 hours of treatment with 2 mmol/L BYL719. E, Increase in cells in G0–G1 and G2–M phase after 24 hours of treatment with 2 mmol/L BYL719. F, GI50 curve of BYL719 only and the addition of 500 nmol/L A-1331852 measured by CellTiter Glo at 3 days. G, Cells were treated with 1 mmol/L BYL719 or 500 nmol/L A-1331852 alone and in combination. Cell viability was measured by Trypan Blue exclusion after 3 days. H, Cells were treated with 1 mmol/L BYL719 or 500 nmol/L A-1331852 alone and in combination. After 24 hours, cellswere harvested and stained for activated caspase- 3 for flow cytometry. For all, error bars show mean SEM. For experiments in B, F, and H; n ¼ 3. For experiments in D and E, n ¼ 5. For experiments in G; n ¼ 6; , P < 0.05; , P < 0.01; , P < 0.005; , P < 0.001.
A Salmonicida Hg3 Atcc 33658tb United Kingdom Fish, supplied by ATCC, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/a+salmonicida+atcc+33658t/10__1128_slash_aem__01357___09-97-213-216?v=ATCC
Average 94 stars, based on 1 article reviews
a salmonicida hg3 atcc 33658tb united kingdom fish - by Bioz Stars, 2026-07
94/100 stars
  Buy from Supplier
agathobacter rectalis  (ATCC)
96
ATCC agathobacter rectalis
Figure 4. Loss of <t>NEDD9</t> or inhibition of BCL-XL renders PIK3CA-mutant gastric cancer cells hypersensitive to BYL719 treatment by increasing cell-cycle arrest and cell death, respectively. A, Western blot of NEDD9 expression in parental and NEDD9-knockout AGS cells. B, GI50 curve of BYL719 in parental and NEDD9-knockout AGS cells measured by CellTiter Glo at 3 days. C, Representative BrdU plots of AGS parental and NEDD9-knockout cells treated with either DMSO or 2 mmol/L BYL719 for 24 hours. D, Reduction in S phase in parental and NEDD9-knockout AGS cells after 24 hours of treatment with 2 mmol/L BYL719. E, Increase in cells in G0–G1 and G2–M phase after 24 hours of treatment with 2 mmol/L BYL719. F, GI50 curve of BYL719 only and the addition of 500 nmol/L A-1331852 measured by CellTiter Glo at 3 days. G, Cells were treated with 1 mmol/L BYL719 or 500 nmol/L A-1331852 alone and in combination. Cell viability was measured by Trypan Blue exclusion after 3 days. H, Cells were treated with 1 mmol/L BYL719 or 500 nmol/L A-1331852 alone and in combination. After 24 hours, cellswere harvested and stained for activated caspase- 3 for flow cytometry. For all, error bars show mean SEM. For experiments in B, F, and H; n ¼ 3. For experiments in D and E, n ¼ 5. For experiments in G; n ¼ 6; , P < 0.05; , P < 0.01; , P < 0.005; , P < 0.001.
Agathobacter Rectalis, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/a+salmonicida+atcc+33658t/pm41240073-39-47-51?v=ATCC
Average 96 stars, based on 1 article reviews
agathobacter rectalis - by Bioz Stars, 2026-07
96/100 stars
  Buy from Supplier
v mimicus atcc 33653t  (ATCC)
91
ATCC v mimicus atcc 33653t
Figure 4. Loss of <t>NEDD9</t> or inhibition of BCL-XL renders PIK3CA-mutant gastric cancer cells hypersensitive to BYL719 treatment by increasing cell-cycle arrest and cell death, respectively. A, Western blot of NEDD9 expression in parental and NEDD9-knockout AGS cells. B, GI50 curve of BYL719 in parental and NEDD9-knockout AGS cells measured by CellTiter Glo at 3 days. C, Representative BrdU plots of AGS parental and NEDD9-knockout cells treated with either DMSO or 2 mmol/L BYL719 for 24 hours. D, Reduction in S phase in parental and NEDD9-knockout AGS cells after 24 hours of treatment with 2 mmol/L BYL719. E, Increase in cells in G0–G1 and G2–M phase after 24 hours of treatment with 2 mmol/L BYL719. F, GI50 curve of BYL719 only and the addition of 500 nmol/L A-1331852 measured by CellTiter Glo at 3 days. G, Cells were treated with 1 mmol/L BYL719 or 500 nmol/L A-1331852 alone and in combination. Cell viability was measured by Trypan Blue exclusion after 3 days. H, Cells were treated with 1 mmol/L BYL719 or 500 nmol/L A-1331852 alone and in combination. After 24 hours, cellswere harvested and stained for activated caspase- 3 for flow cytometry. For all, error bars show mean SEM. For experiments in B, F, and H; n ¼ 3. For experiments in D and E, n ¼ 5. For experiments in G; n ¼ 6; , P < 0.05; , P < 0.01; , P < 0.005; , P < 0.001.
V Mimicus Atcc 33653t, supplied by ATCC, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/a+salmonicida+atcc+33658t/pm10758846-375-82-84?v=ATCC
Average 91 stars, based on 1 article reviews
v mimicus atcc 33653t - by Bioz Stars, 2026-07
91/100 stars
  Buy from Supplier

Image Search Results


Figure 4. Loss of NEDD9 or inhibition of BCL-XL renders PIK3CA-mutant gastric cancer cells hypersensitive to BYL719 treatment by increasing cell-cycle arrest and cell death, respectively. A, Western blot of NEDD9 expression in parental and NEDD9-knockout AGS cells. B, GI50 curve of BYL719 in parental and NEDD9-knockout AGS cells measured by CellTiter Glo at 3 days. C, Representative BrdU plots of AGS parental and NEDD9-knockout cells treated with either DMSO or 2 mmol/L BYL719 for 24 hours. D, Reduction in S phase in parental and NEDD9-knockout AGS cells after 24 hours of treatment with 2 mmol/L BYL719. E, Increase in cells in G0–G1 and G2–M phase after 24 hours of treatment with 2 mmol/L BYL719. F, GI50 curve of BYL719 only and the addition of 500 nmol/L A-1331852 measured by CellTiter Glo at 3 days. G, Cells were treated with 1 mmol/L BYL719 or 500 nmol/L A-1331852 alone and in combination. Cell viability was measured by Trypan Blue exclusion after 3 days. H, Cells were treated with 1 mmol/L BYL719 or 500 nmol/L A-1331852 alone and in combination. After 24 hours, cellswere harvested and stained for activated caspase- 3 for flow cytometry. For all, error bars show mean SEM. For experiments in B, F, and H; n ¼ 3. For experiments in D and E, n ¼ 5. For experiments in G; n ¼ 6; , P < 0.05; , P < 0.01; , P < 0.005; , P < 0.001.

Journal: Molecular Cancer Research

Article Title: CBF-Beta Mitigates PI3K-Alpha–Specific Inhibitor Killing through PIM1 in PIK3CA-Mutant Gastric Cancer

doi: 10.1158/1541-7786.mcr-23-0034

Figure Lengend Snippet: Figure 4. Loss of NEDD9 or inhibition of BCL-XL renders PIK3CA-mutant gastric cancer cells hypersensitive to BYL719 treatment by increasing cell-cycle arrest and cell death, respectively. A, Western blot of NEDD9 expression in parental and NEDD9-knockout AGS cells. B, GI50 curve of BYL719 in parental and NEDD9-knockout AGS cells measured by CellTiter Glo at 3 days. C, Representative BrdU plots of AGS parental and NEDD9-knockout cells treated with either DMSO or 2 mmol/L BYL719 for 24 hours. D, Reduction in S phase in parental and NEDD9-knockout AGS cells after 24 hours of treatment with 2 mmol/L BYL719. E, Increase in cells in G0–G1 and G2–M phase after 24 hours of treatment with 2 mmol/L BYL719. F, GI50 curve of BYL719 only and the addition of 500 nmol/L A-1331852 measured by CellTiter Glo at 3 days. G, Cells were treated with 1 mmol/L BYL719 or 500 nmol/L A-1331852 alone and in combination. Cell viability was measured by Trypan Blue exclusion after 3 days. H, Cells were treated with 1 mmol/L BYL719 or 500 nmol/L A-1331852 alone and in combination. After 24 hours, cellswere harvested and stained for activated caspase- 3 for flow cytometry. For all, error bars show mean SEM. For experiments in B, F, and H; n ¼ 3. For experiments in D and E, n ¼ 5. For experiments in G; n ¼ 6; , P < 0.05; , P < 0.01; , P < 0.005; , P < 0.001.

Article Snippet: Antibody against NEDD9 (Cas-L 2G9; sc-33659) was purchased from Santa Cruz Biotechnology.

Techniques: Inhibition, Mutagenesis, Western Blot, Expressing, Knock-Out, Staining, Cytometry